HOME >> MEDICINE >> NEWS
Interferon with ribavirin is safe and effective for children with chronic Hepatitis C

Nearly half of 118 children with chronic Hepatitis C virus (HCV) treated with a combination of interferon-alpha-2b and an optimized dose of ribavirin achieved sustained viral response, and side effects were generally mild. These results are reported in the November 2005 issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD).

Published by John Wiley & Sons, Inc., Hepatology is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/hepatology.

HCV is usually asymptomatic in children though it can lead to serious liver damage. Treatment with interferon is standard and induces lasting remission in more than a third of infected children. The addition of ribavirin to treatment with interferon has been shown to markedly improve outcomes for adults with HCV, but the combination has not been extensively studied in children. Led by Regino Gonzlez-Peralta, M.D. of the Division of Pediatric Gastroenterology, Hepatology, and Nutrition at the University of Florida, researchers addressed combination therapy for children with a twofold program.

The first part searched for the optimal dose of ribavirin for children with HCV while testing the drug's safety and efficacy. Fifty-six children, ages five to 16, were randomly assigned to take interferon along with ribavirin in varying doses for 48 weeks. They were evaluated for efficacy and side effects at regular intervals, and followed-up for an additional 24 weeks. By the end of the follow-up period, 35 percent of children taking 8 mg/kg/day of ribavirin, 37 percent taking 12 mg/kg/day, and 47 percent of 15/mg/kg/day had undetectable levels of HCV in their blood. Side effects were similar among all doses. Based on this data, the researchers selected the dosage 15 mg/kg/day for further study.

In all, 118 children with HCV received the optimized treatment
'"/>

Contact: David Greenberg
dgreenbe@wiley.com
201-748-6484
John Wiley & Sons, Inc.
1-Nov-2005


Page: 1 2

Related medicine news :

1. Interferon-treated hepatitis C patients likely to experience retinopathy
2. Hepatitis C responds best to combo of ribavirin and interferon, study concludes
3. New treatment effective in counteracting cocaine-induced symptoms
4. Osteoporosis screening and treatment may be cost-effective for selected older men
5. Study shows radiofrequency ablation highly effective in treating kidney tumors
6. New study examines effectiveness of tailored health messages
7. Scaling up HIV prevention programs is cost effective
8. New study shows Rescue Remedy is an effective all-natural stress, anxiety reliever
9. U of M researchers assess effectiveness of computerized physician order entry system
10. Nepalese researchers identify cost-effective treatment for drug-resistant typhoid
11. Meningitis: effectiveness of preventive vaccination demonstrated

Post Your Comments:
(Date:4/28/2015)... Hellen Chen, who is a bestselling author and ... to a study conducted by Washington University, between ... has increased by 20% while the number of unfaithful husbands ... report released this year from the Journal of ... or both spouses admit to infidelity, either physical or emotional ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 Researchers from ... one dose of a steroid prior to pemetrexed (Alimta) ... skin reaction. Click here to read the full ... Scientists from the Raabe College of Pharmacy in Ohio, ... and Appalachian Regional Healthcare in Kentucky gave a single ...
(Date:4/28/2015)... 28, 2015 The buyer power score ... of 5, indicating a medium level of buyer power ... suppliers have equal power during negotiations. One factor helping ... purchasing a health insurance policy from an insurance carrier ... buyers can choose to self-fund their own policy or ...
(Date:4/28/2015)... Louis, Missouri (PRWEB) April 28, 2015 ... report that delves into the reality problem Americans have ... the population will need long-term care services as they ... need such care. , In the report, Carol ... organizations such as the American Health Care Association and ...
(Date:4/28/2015)... OsteoRemedies®, LLC, Memphis, TN, offers ... of infected hip and knee arthroplasty. ... pre-formed, pre-loaded spacer with Gentamicin Antibiotics, for consistent ... Combined with a consistent process for polishing ... approved for temporary use for up to 180 ...
Breaking Medicine News(10 mins):Health News:Why Do Some Good Women and Men End Up Breaking Others' Marriages? 2Health News:Why Do Some Good Women and Men End Up Breaking Others' Marriages? 3Health News:Study Finds New Regimen May Ward Off Skin Rash from Common Mesothelioma Drug, According to Surviving Mesothelioma 2Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 2Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 4Health News:SeniorCare.com Report: America Has a Major Misconception on Aging 2
(Date:4/28/2015)... , April 28, 2015 ANI Pharmaceuticals, ... Company plans to release its first quarter 2015 financial ... of the U.S. financial markets. The earnings press release ... the Company,s website, www.anipharmaceuticals.com . ... Officer, and Charlotte C. Arnold , Vice President ...
(Date:4/28/2015)... CARLOS, Calif. , April 28, 2015  Rosa ... expertise in drug-disease modeling and simulation, today announced its ... in the exciting field of Quantitative Systems Pharmacology (QSP). ... in pharmaceutical drug development.  ... Rosa,s ...
(Date:4/28/2015)...  Boston Scientific Corporation (NYSE: BSX ) ... quarter ended March 31, 2015, compared to the ... to $1.800 billion.  This represents 6 percent operational ... and flat revenue on a reported basis, all ... achieved adjusted earnings per share of $0.21 for ...
Breaking Medicine Technology:ANI Pharmaceuticals Schedules Conference Call for First Quarter 2015 Financial Results 2Rosa & Co. is the Lead Partner for the Quantitative Systems Pharmacology (QSP) Congress in Basel, Switzerland and Will Present the Keynote Address 2Rosa & Co. is the Lead Partner for the Quantitative Systems Pharmacology (QSP) Congress in Basel, Switzerland and Will Present the Keynote Address 3Boston Scientific Announces Results for First Quarter 2015 2Boston Scientific Announces Results for First Quarter 2015 3Boston Scientific Announces Results for First Quarter 2015 4Boston Scientific Announces Results for First Quarter 2015 5Boston Scientific Announces Results for First Quarter 2015 6Boston Scientific Announces Results for First Quarter 2015 7Boston Scientific Announces Results for First Quarter 2015 8Boston Scientific Announces Results for First Quarter 2015 9Boston Scientific Announces Results for First Quarter 2015 10Boston Scientific Announces Results for First Quarter 2015 11Boston Scientific Announces Results for First Quarter 2015 12Boston Scientific Announces Results for First Quarter 2015 13Boston Scientific Announces Results for First Quarter 2015 14Boston Scientific Announces Results for First Quarter 2015 15Boston Scientific Announces Results for First Quarter 2015 16Boston Scientific Announces Results for First Quarter 2015 17Boston Scientific Announces Results for First Quarter 2015 18Boston Scientific Announces Results for First Quarter 2015 19Boston Scientific Announces Results for First Quarter 2015 20Boston Scientific Announces Results for First Quarter 2015 21Boston Scientific Announces Results for First Quarter 2015 22Boston Scientific Announces Results for First Quarter 2015 23Boston Scientific Announces Results for First Quarter 2015 24Boston Scientific Announces Results for First Quarter 2015 25
Cached News: